Kev Tshawb Fawb Txog Kev Tshawb Fawb Pom Zoo Txog Kev Nyab Xeeb thiab Kev Ua Haujlwm Zoo ntawm CD19/CD20 CAR-T Therapy rau r/r B-NHL

Ib txoj kev tshawb fawb tshiab luam tawm hauv Ntshavqhia txog kev txhim kho zoo ntawm prizloncabtagene autoleucel (prizlon-cel), uas yog kev kho mob CD19/CD20-targeting CAR-T cell tshiab, rau kev kho mob B-cell uas rov qab los/tsis ua haujlwm zoo Lymphoma uas tsis yog Hodgkin (r/r B-NHL). Qhov kev sim no, uas yog theem 1, ntau lub chaw, kev tshawb fawb qhib uas tau ua nyob rau hauv Suav teb, muab cov ntaub ntawv zoo txog kev nyab xeeb thiab kev ua tau zoo ntawm txoj hauv kev ob lub hom phiaj no.

Ua raws li pab pawg kws tshawb fawb nto moo los ntawm cov tsev kawm ntawv suav nrog Zhejiang University's First Affiliated Hospital thiab Tongji University, txoj kev tshawb fawb tau sau npe rau 48 tus neeg mob uas muaj r/r B-NHL, feem ntau yog cov neeg mob loj B-Cell Lymphoma (LBCL). Cov neeg mob tau dhau los ua ib txoj kev kho mob nruab nrab ntawm peb kab. Cov neeg koom nrog tau txais ib qho kev txhaj tshuaj ntawm prizlon-cel tom qab lymphodepleting chemotherapy, nrog rau cov koob tshuaj ntau ntawm peb theem (DL1, DL2, thiab DL3).

Cov Ntsiab Lus Tseem Ceeb:

• Cov Ntaub Ntawv Kev Nyab Xeeb: Tsis pom muaj kev lom tshuaj uas txwv tsis pub siv tshuaj ntau (DLT), thiab kev kho mob tau pom tias muaj kev phiv tshuaj uas tswj tau. Cytokine release syndrome (CRS) tshwm sim hauv 93.8% ntawm cov neeg mob, feem ntau yog qib 1-2, tsuas muaj ib qho qib 3 xwb. Immune effector cell-associated neurotoxicity syndrome (ICANS) tsis tshua muaj thiab tsis hnyav heev, tsis muaj qib 3 lossis siab dua.
• Kev ua haujlwm zoo: Tus nqi teb tag nrho (ORR) ntawm 91.5% tau ua tiav, nrog rau tus nqi teb tiav (CR) ntawm 85.1%. Ntawm cov neeg mob LBCL, tus nqi ORR thiab CR yog 90.7% thiab 86.0%, raws li. Qhov zoo kawg nkaus, 48.9% ntawm cov neeg mob tau khaws cia CR ntawm qhov kev saib xyuas zaum kawg, nrog rau qee cov lus teb tshaj peb xyoos.
• Cov Txiaj Ntsig Txog Kev Ciaj Sia: Cov kev kwv yees ntawm Kaplan-Meier qhia tau tias muaj 2 xyoos ntawm kev teb (DOR), kev ciaj sia tsis muaj kev nce qib (PFS), thiab tag nrho kev ciaj sia (OS) ntawm 66.0%, 62.6%, thiab 76.5%, raws li. Hauv cov neeg mob CR, cov nqi no siab dua.

Prizlon-cel tau ua pov thawj tias nws nthuav dav thiab ua haujlwm tau ntev, nrog rau lub sijhawm rov zoo ntawm B-cell nruab nrab ntawm 185 hnub. Nws txoj kev tsim ob lub hom phiaj yog los daws qhov teeb meem ntawm kev khiav tawm ntawm cov antigen, uas yog ib qho kev tiv thaiv uas siv ntau hauv kev kho mob CAR-T.